HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast

In this podcast, Aditya Bardia from the Massachusetts General Hospital, Harvard Medical School in Boston, and Giuseppe Viale from the Department of Pathology and Laboratory Medicine at the European Institute of Oncology in Milan discuss HER2-low breast cancer, including the implications of the recent US FDA and EU approval of trastuzumab deruxtecan (T-DXd) for use in patients with HER2-low breast cancer, the new challenges that this development presents, and ongoing research that will help refine and define HER2-low patient identification.

This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-023-00964-8. All conflicts of interest can be found online.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. 

This podcast in intended for medical professionals.